文献速递免疫规划传染病防控与疫情报告

2022/23季意大利成人流感疫苗预防实验室确诊感染相关就诊的有效性

Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season.
PubMed 文献 · Vaccine · 2023-06-28

该研究采用回顾性检测阴性病例对照设计,在意大利热那亚一家大型三级医院评估2022/23季流感疫苗对成人实验室确诊流感相关就诊的有效性。共纳入487例患者,13%流感阳性,以A(H3N2)为主(63%)。疫苗对所有流感、甲型流感及A(H3N2)的有效性分别为57%(95%CI:11-81%)、53%(95%CI:2-80%)和38%(95%CI:-34-74%)。结论认为该季疫苗对实验室确诊流感相关就诊具有中等有效性。

要点

  • 2022/23季流感疫苗对所有流感相关医院就诊的有效性为57%(95%CI:11-81%)。
  • 疫苗对甲型流感有效性53%(95%CI:2-80%),对A(H3N2)为38%(95%CI:-34-74%)。
  • 接种者中未观察到A(H1N1)pdm09和B型流感病例,但后者检出率低致估计不精确。

核心结论

  • 2022/23季季节性流感疫苗对实验室确诊流感相关医院就诊具有中等有效性。

研究设计与样本

  • 采用回顾性检测阴性病例对照设计,于2022年10月至2023年4月在意大利热那亚一家大型三级医院开展。
  • 研究对象为≥18岁因急性呼吸道感染症状至急诊就诊并接受流感病毒逆转录实时聚合酶链反应检测的成人患者。
  • 共评估33692例转诊,最终纳入487例患者。

主要发现

  • 13%的患者流感阳性,其中63%为A(H3N2)亚型。
  • 疫苗对所有流感的有效性为57%(95%CI:11-81%)。
  • 疫苗对甲型流感的有效性为53%(95%CI:2-80%)。
  • 疫苗对A(H3N2)的有效性为38%(95%CI:-34-74%)。
  • 接种者中未观察到A(H1N1)pdm09和B型流感病例,但因检出率低,对后者的疫苗有效性估计不精确。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The effectiveness of seasonal influenza vaccination (SIV) varies from year to year. Interim estimates of vaccine effectiveness (VE) in outpatient settings have suggested that the 2022/23 northern hemisphere SIV was 54 % effective. The main goal of this study was to measure the 2022/23 SIV VE among Italian adults in a hospital setting. The study adopted a retrospective test-negative case-control design and was conducted in a large tertiary hospital (Genoa, Italy) between October 2022 and April 2023. Adult (≥18 years) patients accessing the hospital's Emergency Department for symptoms ascribable to an acute respiratory infection, for which a reverse-transcription real-time polymerase chain reaction test for the detection of influenza virus was prescribed, were potentially eligible. Of 33,692 referrals assessed, 487 patients were included in the study. A total of 13 % of patients were positive for influenza, most of which (63 %) belonged to the A(H3N2) subtype. SIV VE was 57 % (95 % CI: 11-81 %), 53 % (95 % CI: 2-80 %) and 38 % (95 % CI: -34-74 %) against any influenza, influenza A and A(H3N2), respectively. Although no cases caused by A(H1N1)pdm09 and B strains were observed among vaccinated individuals, VE estimates against the latter were imprecise, owing to their low detection rates. In conclusion, the 2022/23 SIV was moderately effective against hospital encounters for laboratory-confirmed influenza.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Domnich A, Orsi A, Ogliastro M, et al. Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season. Vaccine. 2023. PMID: 37385889. doi:10.1016/j.vaccine.2023.06.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。